Zinc toxicity: Difference between revisions

(Text replacement - "Poison Control Center" to "poison control")
No edit summary
Line 25: Line 25:
**Rhinitis
**Rhinitis
**[[Dyspnea]]
**[[Dyspnea]]
**[[Acute lung injury]]
**Acute lung injury
**[[Acute Respiratory Distress Syndrome]]
**[[Acute Respiratory Distress Syndrome]]
**[[Metal fume fever]]
**Metal fume fever


===Chronic===
===Chronic===
*Zinc induced copper deficiency
*Zinc induced copper deficiency
**Reversible [[sideroblastic anemia]]
**Reversible sideroblastic [[anemia]]
**Reversible [[myelodysplastic syndrome]]
**Reversible [[myelodysplastic syndrome]]
*Progressive myeloneuropathy
*Progressive myeloneuropathy
**Spastic gait
**Spastic gait
**Sensory ataxia
**Sensory [[ataxia]]


==Differential Diagnosis==
==Differential Diagnosis==
Line 53: Line 53:
**Supportive Care
**Supportive Care
***Hydration
***Hydration
***H<sub>2</sub> receptor antagonists or PPI
***[[H2 blocker|H<sub>2</sub> receptor antagonists]] or [[PPI]]
***Antiemetics
***[[Antiemetics]]
**Consider whole bowel irrigation
**Consider whole bowel irrigation
*Inhalation
*Inhalation
**Supportive care
**Supportive care
***Oxygen therapy
***[[Oxygen therapy]]
***Bronchodilators
***[[Bronchodilators]]
**Metal fume fever
**Metal fume fever
***Usually self limiting
***Usually self limiting
Line 66: Line 66:
**Limited data on use, and data present is based off of case reports and treatment for lead toxicity <ref>Majlesi, N. Zinc. In: Goldfrank's Toxicologic Emergencies. 9th Ed. New York: McGraw-Hill; 2011: 1342</ref>
**Limited data on use, and data present is based off of case reports and treatment for lead toxicity <ref>Majlesi, N. Zinc. In: Goldfrank's Toxicologic Emergencies. 9th Ed. New York: McGraw-Hill; 2011: 1342</ref>
**Consider in patients with hemodynamic compromise
**Consider in patients with hemodynamic compromise
**CaNa<sub>2</sub>EDTA, British anti-Lewisite, DTPA were all successfully used in case reports
**CaNa<sub>2</sub>[[EDTA]], [[British antilewisite]], DTPA were all successfully used in case reports
**1000mg/m<sup>2</sup>/d IV CaNa<sub>2</sub>EDTA every 6 hours
**1000mg/m<sup>2</sup>/d IV CaNa<sub>2</sub>EDTA every 6 hours
***Based on a successful case report, but should be given in conjunction with toxicology or poison control center
***Based on a successful case report, but should be given in conjunction with toxicology or poison control center

Revision as of 01:10, 27 January 2019

Background

  • Transition metal
  • Essential nutrient
  • Exposure from diet, medicinal uses, nutritional supplements, and occupational exposures
    • Multiple case reports of zinc toxicity related to ingestion of United States pennies which contain 97.5% zinc

Toxicokinetics

  • Absorbed primarily in the jejunum
  • Excreted via the GI tract with minimal amounts excreted in the urine
  • Accumulates in erythrocytes
    • Whole blood concentrations are 6-7x higher than in the serum
  • Inverse relationship with copper
    • Excess zinc absorption will cause a counterregulatory response resulting in copper elimination

Clinical Features

Acute

Chronic

Differential Diagnosis

Evaluation

  • BMP
  • CBC
  • Copper level
  • Ceruloplasmin level
  • Abdominal films to assess for foreign bodies
  • MRI
    • Will show increase T2 signal in the dorsal columns of the cervical cord

Management

  • Oral toxicity
  • Inhalation
  • Chelation
    • Limited data on use, and data present is based off of case reports and treatment for lead toxicity [1]
    • Consider in patients with hemodynamic compromise
    • CaNa2EDTA, British antilewisite, DTPA were all successfully used in case reports
    • 1000mg/m2/d IV CaNa2EDTA every 6 hours
      • Based on a successful case report, but should be given in conjunction with toxicology or poison control center
  • Dermal Exposures
    • Do not use water in metallic zinc exposures
      • Concern metal will ignite
    • Remove zinc with forceps and apply mineral oil to affected skin
  • Copper replacement
    • Oral copper alone shown to improve hematopoietic effects and prevent further neurological deterioration [2]

Disposition

References

  1. Majlesi, N. Zinc. In: Goldfrank's Toxicologic Emergencies. 9th Ed. New York: McGraw-Hill; 2011: 1342
  2. Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry. 2005;76:750-751.

Majlesi, N. Zinc. In: Goldfrank's Toxicologic Emergencies. 9th Ed. New York: McGraw-Hill; 2011: 1339-1344